These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34805377)

  • 41. Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.
    Reiner Ž
    Korean Circ J; 2018 Dec; 48(12):1097-1119. PubMed ID: 30403015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia.
    Hooper AJ; Kurtkoti J; Hamilton-Craig I; Burnett JR
    Ann Clin Biochem; 2014 Jul; 51(Pt 4):485-9. PubMed ID: 24591733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text.
    Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG
    Curr Vasc Pharmacol; 2019; 17(5):498-514. PubMed ID: 31060488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
    Takeda Y; Sakuma I; Hiramitsu S; Okada M; Ueda S; Sakurai M
    Front Cardiovasc Med; 2023; 10():1094100. PubMed ID: 36760560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
    Calcaterra I; Lupoli R; Di Minno A; Di Minno MND
    Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Shepherd J; Betteridge J; Van Gaal L;
    Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
    Tenenbaum A; Klempfner R; Fisman EZ
    Cardiovasc Diabetol; 2014 Dec; 13():159. PubMed ID: 25471221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertriglyceridaemia in adolescents may have serious complications.
    Korf M; Zöllner EW; Solomon GEA; Zemlin AE; Marais AD
    S Afr Med J; 2022 Apr; 112(5):307-312. PubMed ID: 35587241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Familial dyslipidaemias: an overview of genetics, pathophysiology and management.
    Hachem SB; Mooradian AD
    Drugs; 2006; 66(15):1949-69. PubMed ID: 17100406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical review on triglycerides.
    Laufs U; Parhofer KG; Ginsberg HN; Hegele RA
    Eur Heart J; 2020 Jan; 41(1):99-109c. PubMed ID: 31764986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An updated review of lipid-modifying therapy.
    Simons LA
    Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
    Farnier M; Zeller M; Masson D; Cottin Y
    Arch Cardiovasc Dis; 2021 Feb; 114(2):132-139. PubMed ID: 33546998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary and secondary hypertriglyceridaemia.
    Kolovou GD; Anagnostopoulou KK; Kostakou PM; Bilianou H; Mikhailidis DP
    Curr Drug Targets; 2009 Apr; 10(4):336-43. PubMed ID: 19355858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.